Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01553214 · ClinicalTrials.gov registry record · Phase 4
Improving White Blood Cell Collection From Healthy Donors
A Phase 4 study of Allogeneic Granulocyte Donation, sponsored by National Institutes of Health Clinical Center (CC).
- Recruiting
- Registry status
- Phase 4
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT01553214 is a Phase 4 study of Allogeneic Granulocyte Donation that is actively recruiting participants, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 1,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01553214, a Phase 4 study of Allogeneic Granulocyte Donation, is actively recruiting participants, sponsored by National Institutes of Health Clinical Center (CC).
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- White blood cells called granulocytes help the body fight infection. People who have had chemotherapy or bone marrow transplants may have very low numbers of these cells. Transfusions of these cells can help improve the body's ability to fight infection. However, most of the cells are located in the bone marrow or spleen, and are hard to collect from healthy donors. Two drugs, filgrastim and dexamethasone, can help move the cells to the bloodstream to be collected by apheresis. Researchers want to study the best ways to collect these white blood cells. They also want to monitor the effects of the injections and donations on the volunteer donors. Objectives: \- To improve the amount and quality of granulocytes (white blood cells) collected by apheresis for donation. Eligibility: \- Healthy volunteers between 18 and 75 years of age. Design: * Participants will be screened with a physical exam and medical history. Initial blood tests will be done to check for eligibility. * Participants will donate granulocytes by apheresis a maximum of 12 times in 1 year. Donations will not usually be requested more often than every 4 weeks. Donors will be allowed to decline participation at any time. * Participants will have one injection of filgrastim 12 to 24 hours before donation. They will also have two tablets of dexamethasone 12 hours before donation. * White blood cells will be collected through apheresis. The apheresis will last about 2 hours. * Participants will be eligible to donate until they reach their 76th birthday.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Filgrastim
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2012-12-31 |
| Est. Completion | 2032-01-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01553214
The ClinicalTrials.gov registry entry for NCT01553214 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allogeneic Granulocyte Donation appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01553214 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01553214 about?
NCT01553214 is a clinical study titled "Improving White Blood Cell Collection From Healthy Donors". Background: \- White blood cells called granulocytes help the body fight infection. People who have had chemotherapy or bone marrow transplants may have very low numbers of these cells. Transfusions of these cells can help improve the body's ability to fight infection. However, most of the cells ar...
What is the current status of trial NCT01553214?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 1,000 participants. The study started on 2012-12-31. Estimated completion is 2032-01-01.
What conditions does trial NCT01553214 study?
This clinical trial studies the following conditions: Allogeneic Granulocyte Donation.
What interventions are being tested in trial NCT01553214?
The interventions under investigation include: Dexamethasone (DRUG), Filgrastim (DRUG).
Who is sponsoring clinical trial NCT01553214?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01553214 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.